Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.

Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed what Bloomberg called a "shocking first miss" in its most recent quarterly sales announcement: in spite of bottomless hype ...

Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Novo and Lilly are also working on oral weight loss drugs ... has another pill, amycretin. A phase 1 trial of amycretin released in September showed promising results. Meanwhile, Eli Lilly ...

Nov 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections. The results ...